Biotech Values

[oc631]

Shunned Gilead/Bristol-Myers hep C combo may be too good for docs to ignore

Shame on BMY for not making a higher bid for VRUS. BMY's gamble on INHX confirmed their ignorance of what was going on in the HCV space at that given point of time.